PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
Positive EBIT growth while AVXL is negative. John Neff might see a substantial edge in operational management.
-2.64%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
0.38%
Positive net income growth while AVXL is negative. John Neff might see a big relative performance advantage.
3.04%
Positive EPS growth while AVXL is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
3.04%
Positive diluted EPS growth while AVXL is negative. John Neff might view this as a strong relative advantage in controlling dilution.
2.54%
Share count expansion well above AVXL's 1.41%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
2.54%
Diluted share count expanding well above AVXL's 1.41%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
10.47%
Positive OCF growth while AVXL is negative. John Neff would see this as a clear operational advantage vs. the competitor.
10.65%
Positive FCF growth while AVXL is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-37006.68%
Negative 5Y OCF/share CAGR while AVXL is at 67.35%. Joel Greenblatt would question the firm’s operational model or cost structure.
-70.29%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-15642.97%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-43858.45%
Negative 5Y net income/share CAGR while AVXL is 74.87%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-130.01%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
5Y equity/share CAGR above 1.5x AVXL's 239.55%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
1066.60%
3Y equity/share CAGR above 1.5x AVXL's 145.70%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-27.26%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
37.07%
We increase R&D while AVXL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
-49.28%
We cut SG&A while AVXL invests at 61.40%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.